Ipsen’s aim to develop a pipeline of rare bone disease therapies is partly back on track with the news that it is planning to restart the global Phase III MOVE study of palovarotene in patients aged 14 years or over with fibrodysplasia ossificans progressive (FOP).
However, the US Food and Drug Administration’s partial hold on clinical studies of the drug in patients aged under 14...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
